Medpace Holdings Inc vs Spotify Technology — how do they compare? Medpace Holdings Inc trades at $530.32 (market cap $15.08B), while Spotify Technology trades at $490.01 (market cap $101.23B). The key difference: Spotify Technology is far larger — about 6.7× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Spotify Technology nearer its low. Which is the better fit depends on your goals.
| MEDP | SPOT | |
|---|---|---|
Market Cap | $15.08B | $101.23B |
Sector | Technology | Media |
52-Week High | $620.59 | $738.53 |
52-Week Low | $308.88 | $412.75 |
Enterprise Value | $14.55B | $91.81B |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Spotify (SPOT) trades at $493.49, up 3.21% today, showing strong momentum after recent earnings beats. The stock faces technical resistance near $498 with bearish moving average signals. Fundamentally, the company demonstrates impressive growth with revenue reaching $17.19B in 2025 and net income surging to $2.21B, representing a 12.87% margin. Recent AI integration initiatives and expanded family account features highlight ongoing innovation.
Wall Street maintains a bullish stance with 61.5% buy ratings and a $617 consensus target, representing 25% upside potential. However, elevated valuation multiples (P/E 32.6, P/S 5.0) and competitive pressures from streaming rivals present near-term risks. The Q2 2026 earnings report will be crucial for validating the current growth trajectory.
Trailing returns across standard periods
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →